A molecular diagnostics company focused on the early detection of cancer through noninvasive screening tests. Its flagship products include stool‑based DNA tests for colorectal cancer and a growing pipeline of liquid biopsy and genomic assays aimed at detecting multiple cancers at earlier stages. In...
1 member of Congress has disclosed 1 trade in 25780 (EXAC), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2012-08-04 | Curtis J. Clawson | sell | $15K – $50K |